

Nagrody i wyróżnienia naukowe

rodzaj wyróżnienia/nagrody	rok otrzymania
Zespołowa Nagroda Ministra Zdrowia	2003
Zespołowa Nagroda Rektora Akademii/ Uniwersytetu Medycznego w Białymstoku	2002, 2003, 2004, 2006, 2008, 2013, 2017, 2018

Wykaz prac opublikowanych w latach 2020-2001

(dane z dnia 2020-09-16 wg <http://biblioteka.umb.edu.pl/cgi-bin/expertus.cgi>)

współczynnik Hirscha = 7

IF = **51.006**

punktacja ministerstwa = 752

2020 rok

Rożkiewicz D., Hermanowicz J., TANKIEWICZ-KWEDLO A., Sieklucka B., Pawlak K., Czarnomysy R., Bielawski K., Surażyński A., Kalafut J., Przybyszewska A., Koda M., Jakubowska K., Rivero-Muller A., Pawlak D.: *The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer*. **J Enzyme Inhib Med Chem** 35, 1697-1711, 2020. doi: 1080/14756366.2020.1818738

Karbowska M., Hermanowicz J., TANKIEWICZ-KWEDLO A., Kałaska B., Kamiński T., Nosek K., Wiśniewska R., Pawlak D.: *Neurobehavioral effects of uremic toxin-indoxyl sulfate in the rat model*. **Sci Rep** 2020 : 10, 14, 2020 doi: 10.1038/s41598-020-66421-y

2019 rok

Wróbel A., Kolesińska B., Frączyk J., Kamiński ZJ, TANKIEWICZ-KWEDLO A, Hermanowicz J, Czarnomysy R, Maliszewski D, Drozdowska D.: *Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines*. **Invest New Drugs** 38, 990-1002, 2020. doi:10.1007/s10637-019-00838-9

2018 rok

TANKIEWICZ-KWEDLO A, Hermanowicz JM, Pawlak K, Czarnomysy R, Bielawski K, Prokop I, Pawlak D.: *Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer*. **Int J Mol Sci**. 19, 2018. pii: E1262. doi: 10.3390/ijms19041262.

TANKIEWICZ-KWEDLO A, Hermanowicz JM, Domaniewski T, Pawlak K, Rusak M, Pryczynicz A, Surazynski A, Kaminski T, Kazberuk A, Pawlak D.: *Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer*. **Br J Pharmacol**. 175, 743-762, 2018. doi: 10.1111/bph.14099.

2017 rok

Bartosiewicz J, Kaminski T, Pawlak K, Karbowska M, TANKIEWICZ-KWEDLO A, Pawlak D.: *The activation of the kynurenine pathway in a rat model with renovascular hypertension*. **Exp Biol Med** (Maywood). 242, 750-761, 2017. doi: 10.1177/1535370217693114.

TANKIEWICZ-KWEDLO A, Hermanowicz JM, Surazynski A, Kwedlo W, Rozkiewicz D, Pawlak K, Domaniewski T, Pawlak D.: *Erythropoietin Enhances the Cytotoxic Effect of Hydrogen Peroxide on Colon Cancer Cells*. **Curr Pharm Biotechnol**. 18, 127-137, 2017. doi: 10.2174/1389201018666161116092907.

2016 rok

TANKIEWICZ-KWEDLO A, Hermanowicz J, Surazynski A, Rożkiewicz D, Pryczynicz A, Domaniewski T, Pawlak K, Kemon A, Pawlak D.: *Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts*. **Mol Cell Biochem**. 421, 1-18, 2016. doi: 10.1007/s11010-016-2779-x.

2015 rok

Hermanowicz JM., Buczek P., TANKIEWICZ-KWEDLO A., Hermanowicz A., Buczek W. *Impact of aliskiren on some hemostatic parameters in experimental arterial thrombosis in rats*. **Pharmacol Rep**. 67, 173-178, 2015.

Lewkowicz J, Knapp M, TANKIEWICZ-KWEDLO A, Sawicki R, Kamińska M, Waszkiewicz E, Musiał WJ.: *MMP-9 in atrial remodeling in patients with atrial fibrillation*. **Annales de Cardiologie et d'Angéiologie**, 2015;64:285-291

2013 rok

Hermanowicz JM., Hermanowicz A., Buczek P., Leszczyńska A., TANKIEWICZ-KWEDLO A., Mogielnicki A., Buczek W.: *Aliskiren inhibits experimental venous thrombosis in two-kidney one-clip hypertensive rats*. **Thromb Res**. 131, 39 – 44, 2013.

Lewkowicz J., B. Sobkowicz B., TANKIEWICZ-KWEDLO A., Skibińska E. *Rzadka przyczyna nawracającego, opornego na leczenie migotania przedsionków*. **Pol Przegl Kardiol**. 15, 231-233, 2013.

2010 rok

TANKIEWICZ-KWEDLO A., Pawlak D., Domaniewski T., Buczek W.: *Erythropoietin increases Epo and EpoR expression in DLD-1 cells*. **Pol. Ann. Med**. 17, 16-24, 2010.

TANKIEWICZ-KWEDLO A., Pawlak D., Domaniewski T., Buczek W.: *Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells*. **Pharmacol Rep**. 62, 926-937, 2010.

2008 rok

Kucharewicz I., Kasacka I., Pawlak D., TANKIEWICZ-KWEDLO A., Mroczko B., Buczek W., Bodzenta-Lukaszyk A.: *The concentration of kynurenine in rat model of asthma*. **Folia Histochem Cytobiol**. 46, 199-203, 2008.

2007 rok

Buczek P., TANKIEWICZ-KWEDLO A., Buraczewska A., Myśliwiec M., Pawlak D.: *Accumulation of kynurenine pathway metabolites in saliva and plasma of uremic patients*. **Pharmacol Rep**. 59 (suppl. 1), 199-204, 2007.

Kasacka I., Szarmach I.J., Buczek P., TANKIEWICZ-KWEDLO A., Łapińska J.: *Contrastive analysis of saliva morphology in food allergic and non-allergic patients in initial treatment with fixed orthodontic appliances*. **Pol J Environ Stud**. 16,135-138, 2007.

Kasacka I., Szarmach I.J., Buczek P., TANKIEWICZ-KWEDLO A., Łapińska J.: *Preliminary evaluation of morphological parameters of saliva in patients subjected to orthodontic treatment with amalgam restorations.* **Pol J Environ Stud.** 16, 132-134, 2007.

Szarmach I.J., Buczek P., TANKIEWICZ-KWEDLO A., Kasacka I., Tankiewicz J., Pawlak D.: *The concentration of kynurenine and anthranilic acid in saliva of patients with fixed orthodontic appliances.* **Pol J Environ Stud.** 16, 125-127, 2007.

TANKIEWICZ-KWEDLO A., Buczek P., Dziemiańczyk-Pakiela D., Szarmach I.J., Grabowska S.Z., Topczewska-Bruns J., Pawlak D.: *Tryptophan metabolism in patients with oral squamous cell carcinoma.* **Pol J Environ Stud.** 16, 120-124, 2007.

2006 rok

TANKIEWICZ A., Buczek P., Szarmach I.J., Kasacka I., Pawlak D.: *The concentration of anthranilic acid in saliva of orthodontic appliances.* **Adv Med Sci.** 51 (suppl. 1), 31-33, 2006.

TANKIEWICZ A., Dziemiańczyk D., Buczek P., Szarmach I.J., Grabowska S.Z., Pawlak D.: *Tryptophan and its metabolites in patients with oral squamous cell carcinoma: preliminary study.* **Adv Med Sci.** 51 (suppl. 1), 221-224, 2006.

Szarmach I.J., Kasacka I., Buczek P., TANKIEWICZ A., Pawlak D.: *Oral cavity status and IgE level in orthodontic patients.* **Adv Med Sci.** 51 (suppl. 1), 210-212, 2006.

Kasacka I., Szarmach I.J., Buczek P., TANKIEWICZ A., Pawlak D.: *Preliminary evaluation of morphological parameters of the saliva in patients undergoing orthodontic treatment.* **Adv Med Sci.** 51 (suppl. 1), 52-54, 2006.

Kasacka I., Szarmach I.J., Buczek P., TANKIEWICZ A., Pawlak D.: *Preliminary evaluation of saliva composition in allergic patients subjected to orthodontic treatment ; morphological examination.* **Adv Med Sci.** 51 (suppl. 1), 55-58, 2006.

2005 rok

TANKIEWICZ A., Pawlak D., Pawlak K., Szewc D., Mysliwiec M., Buczek W.: *Anthranilic Acid-uraemic Toxin Damaged Red Cell's Membrane.* **Int Urol Nephrol.** 37, 621-7, 2005.

2004 rok

Cattaneo D., TANKIEWICZ A., Merlini S., Perico N., Remuzzi G.: *Pharmacogenetics of immunosuppressive agents: perspective for individualized therapy.* **Personal Med.** 1, 53-62, 2004.

2003 rok

TANKIEWICZ A., Pawlak D., Topczewska-Bruns J., Buczek W.: *Kidney and liver kynurenine pathway enzymes in chronic renal failure.* **Adv Exp Med Biol.** 527, 409-414, 2003.

Topczewska-Bruns J., Pawlak D., TANKIEWICZ A., Chabielska E., Buczek W.: *Kynurenine metabolism in central nervous system in experimental chronic renal failure.* **Adv Exp Med Biol.** 527, 177-182, 2003.

Pawlak D., TANKIEWICZ A., Matys T., Buczek W.: *Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure.* **J Physiol Pharmacol.** 54, 175-189, 2003.

2002 rok

Azzadin A., Malyszko J., Malyszko J.S., TANKIEWICZ A., Mysliwiec M., Buczek W.: *Effects of combination of cyclosporine with losartan or enalapril on kidney function in uremic rats.* **Pol J Pharmacol.** 54, 469-473, 2002.

Topczewska-Bruns J, Pawlak D, Chabielska E, TANKIEWICZ A, Buczek W.: *Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency.* **Brain Res Bull.** 58, 423-428, 2002.

Pawlak D., TANKIEWICZ A., Mysliwiec P., Buczek W.: *Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure.* **Nephron** 90, 328-335, 2002.

2001 rok

TANKIEWICZ A., Pawlak D., Buczek W.: *Enzymes of the kynurenine pathway.* **Postepy Hig Med Dosw.** 2001; 55, 715-731, 2001.

Topczewska-Bruns J., TANKIEWICZ A., Pawlak D., Buczek W.: *Behavioral changes in the course of chronic renal insufficiency in rats.* **Pol J Pharmacol.** 53, 263-269, 2001.

Pawlak D., TANKIEWICZ A., Buczek W.: *Kynurenine and its metabolites in the rat with experimental renal insufficiency.* **J Physiol Pharmacol.** 52, 755-766, 2001.

Andrzejewska-Buczek J., Pawlak D., TANKIEWICZ A., Matys T., Buczek W.: *Possible involvement of kynurenamines in the pathogenesis of cataract in diabetic patients.* **Med Sci Monit.** 7, 742-745, 2001.